AstraZeneca’s IMFINZI improves lung cancer survival
Positive results emerge from AEGEAN phase 3 trial for patients with resectable non-small cell lung cancer
Read More
Tag: Imfinzi
Imfinzi, tremelimumab combo boosts survival in lung cancer
The POSEIDON trial is the first Phase III study to demonstrate an overall survival benefit with tremelimumab
Read More
AZ withdraws Imfinzi indication in the US for advanced bladder cancer
Decision made in consultation with the FDA following disappointing trial results
Read More
AZ’s Imfinzi fails to improve overall survival in head and neck cancer again
Immunotherapy has previously failed in this therapy area
Read More
FDA approves new dosing option for AZ’s Imfinzi
Less-frequent, fixed-dose use approved for two cancer indications
Read More
AZ’ Imfinzi bags new approval for lung cancer
The EC has cleared its use for the treatment of extensive-stage small cell lung cancer
Read More
Priority review for Imfinzi’s less-frequent dosing regimen
AZ says approval would “simplify and improve treatment by enabling continuity of care while minimising the risk of exposure to infection in the healthcare setting”
Read More
AZ links with ArcherDX to detect minimal residual disease in lung cancer patients
ArcherDX will perform whole exome sequencing of NSCLC patient samples to generate personalised ctDNA assays to test for MRD
Read More
Imfinzi shows survival benefit in aggressive lung cancer
The drug cut the risk of death by 27%.
Read More
AZ’ Imfinzi combo fails lung cancer study
The drug giant reported that in the primary analysis population the combination did not meet the primary endpoint.
Read More
Imfinzi found to improve survival in small cell lung cancer
Limited treatment options are available for patients with this most aggressive type of lung cancer.
Read More
AZ’ Imfinzi to be funded for NHS use via CDF
AstraZeneca’s PD-L1 inhibitor Imfinzi will be made available on the NHS in England immediately for patients with locally advanced unresectable non-small-cell lung cancer.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
